KKR to take Integer private for $5.7B
KKR agreed to buy Integer Holdings for about $5.7B in an all-cash deal, taking Integer private. The transaction is expected to close before year-end, subject to regulatory approvals and shareholder support. Integer stockholders would receive about $127 per share, a 51%+ premium to April 29. Integer reported $464M Q2 sales, down 2.6%.
How this was made
The 30-second read
Why it matters
The disclosed all-cash consideration and premium create a near-term trading catalyst for ITGR via deal-spread dynamics, while KKR faces execution and regulatory approval risk.
Market read
A $5.7B take-private deal with a stated per-share price and premium is a material, time-sensitive M&A catalyst for both KKR and ITGR.
What to watch
The article cites regulatory approvals and shareholder support but does not specify antitrust jurisdiction, financing structure, or any conditions that could delay or derail closing.
Background
Integer launched a strategic review in April due to strong interest, and the KKR offer follows that process.
Ticker impact
KKR agreed to buy Integer Holdings for about $5.7B in an all-cash deal expected to close before year-end.
Likely supportive for KKR sentiment, but near-term trading may hinge on deal certainty and regulatory headlines.
The article discloses deal size, structure, and expected timing, but provides no regulatory outcome or financing details.
Integer agreed to be taken private by KKR in an all-cash transaction valuing the company at about $5.7B.
Supportive bias while the offer is active, with volatility around regulatory approvals and shareholder support.
The article provides offer premium, per-share consideration, and deal timeline, plus notes the stock jumped nearly 20% on the report.
Market effects
Could signal continued consolidation appetite in medical device contract development and manufacturing (CDMO) services.
Primarily US-listed medtech M&A sentiment, with limited direct regional spillover mentioned.
Cross-border investors may view the deal as evidence of sustained global appetite for medtech manufacturing assets.
Counterpoint
Premium offers can still face deal risk; regulatory approvals or shareholder opposition could compress the spread quickly.
Key entities
- acquirerKKR
Global investment firm agreeing to buy Integer Holdings for about $5.7B in an all-cash transaction.
- targetInteger Holdings
Medical device contract development and manufacturing organization agreeing to be taken private by KKR.
